| Dr Benjamin Burke Clippinger, MD | |
|
60 Old New Milford Rd Ste 3e, Brookfield, CT 06804-2414 | |
| (203) 775-6205 | |
| Not Available |
| Full Name | Dr Benjamin Burke Clippinger |
|---|---|
| Gender | Male |
| Speciality | Hand Surgery |
| Experience | 10 Years |
| Location | 60 Old New Milford Rd Ste 3e, Brookfield, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619380276 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 65828 (Connecticut) | Secondary |
| 207XS0106X | Orthopaedic Surgery - Hand Surgery | 65828 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Danbury Hospital | Danbury, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Orthopaedic Specialists Of Connecticut, Pc | 6709779887 | 16 |
News Archive
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.
Quad-City Times: "A proposed change in Medicare reimbursement could increase payments to Iowa hospitals by more than $12.5 million next year. At the same time, a rule change on reimbursement to doctors could boost their Medicare payments by 5 percent beginning next year. 'This will mean a great deal to Iowa hospitals that have been struggling for many years,' said U.S. Rep. Bruce Braley, D-Iowa.
Prasco Laboratories announced today that they have signed a distribution and supply agreement with Stiefel Laboratories, Inc., a GlaxoSmithKline company, for Clobetasol Propionate Foam 0.05%, the latest product in Prasco's line of authorized generics. Under the terms of the agreement, Prasco will market and distribute Clobetasol Propionate Foam 0.05% in 50g and 100g canisters in the U.S. under the Prasco label.
Lipid Therapeutics announces today that it has successfully filed its first US IND for its lead product LT-02 and is now in a position to proceed with a planned Phase III trial in the US in mild-moderate ulcerative colitis patients. The LT-02 IND was subject to the FDA's customary 30 day review period.
The 2010 report on universal access to HIV prevention, care and treatment released today by WHO, UNAIDS, and UNICEF shows continuing progress in scaling up global HIV/AIDS interventions.
› Verified 3 days ago
| Entity Name | Danbury Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548293343 PECOS PAC ID: 1557273935 Enrollment ID: O20031104000476 |
News Archive
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.
Quad-City Times: "A proposed change in Medicare reimbursement could increase payments to Iowa hospitals by more than $12.5 million next year. At the same time, a rule change on reimbursement to doctors could boost their Medicare payments by 5 percent beginning next year. 'This will mean a great deal to Iowa hospitals that have been struggling for many years,' said U.S. Rep. Bruce Braley, D-Iowa.
Prasco Laboratories announced today that they have signed a distribution and supply agreement with Stiefel Laboratories, Inc., a GlaxoSmithKline company, for Clobetasol Propionate Foam 0.05%, the latest product in Prasco's line of authorized generics. Under the terms of the agreement, Prasco will market and distribute Clobetasol Propionate Foam 0.05% in 50g and 100g canisters in the U.S. under the Prasco label.
Lipid Therapeutics announces today that it has successfully filed its first US IND for its lead product LT-02 and is now in a position to proceed with a planned Phase III trial in the US in mild-moderate ulcerative colitis patients. The LT-02 IND was subject to the FDA's customary 30 day review period.
The 2010 report on universal access to HIV prevention, care and treatment released today by WHO, UNAIDS, and UNICEF shows continuing progress in scaling up global HIV/AIDS interventions.
› Verified 3 days ago
| Entity Name | Orthopaedic Specialists Of Connecticut, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366468837 PECOS PAC ID: 6709779887 Enrollment ID: O20040203000828 |
News Archive
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.
Quad-City Times: "A proposed change in Medicare reimbursement could increase payments to Iowa hospitals by more than $12.5 million next year. At the same time, a rule change on reimbursement to doctors could boost their Medicare payments by 5 percent beginning next year. 'This will mean a great deal to Iowa hospitals that have been struggling for many years,' said U.S. Rep. Bruce Braley, D-Iowa.
Prasco Laboratories announced today that they have signed a distribution and supply agreement with Stiefel Laboratories, Inc., a GlaxoSmithKline company, for Clobetasol Propionate Foam 0.05%, the latest product in Prasco's line of authorized generics. Under the terms of the agreement, Prasco will market and distribute Clobetasol Propionate Foam 0.05% in 50g and 100g canisters in the U.S. under the Prasco label.
Lipid Therapeutics announces today that it has successfully filed its first US IND for its lead product LT-02 and is now in a position to proceed with a planned Phase III trial in the US in mild-moderate ulcerative colitis patients. The LT-02 IND was subject to the FDA's customary 30 day review period.
The 2010 report on universal access to HIV prevention, care and treatment released today by WHO, UNAIDS, and UNICEF shows continuing progress in scaling up global HIV/AIDS interventions.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Benjamin Burke Clippinger, MD 60 Old New Milford Rd Ste 3e, Brookfield, CT 06804-2414 Ph: (203) 775-6205 | Dr Benjamin Burke Clippinger, MD 60 Old New Milford Rd Ste 3e, Brookfield, CT 06804-2414 Ph: (203) 775-6205 |
News Archive
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.
Quad-City Times: "A proposed change in Medicare reimbursement could increase payments to Iowa hospitals by more than $12.5 million next year. At the same time, a rule change on reimbursement to doctors could boost their Medicare payments by 5 percent beginning next year. 'This will mean a great deal to Iowa hospitals that have been struggling for many years,' said U.S. Rep. Bruce Braley, D-Iowa.
Prasco Laboratories announced today that they have signed a distribution and supply agreement with Stiefel Laboratories, Inc., a GlaxoSmithKline company, for Clobetasol Propionate Foam 0.05%, the latest product in Prasco's line of authorized generics. Under the terms of the agreement, Prasco will market and distribute Clobetasol Propionate Foam 0.05% in 50g and 100g canisters in the U.S. under the Prasco label.
Lipid Therapeutics announces today that it has successfully filed its first US IND for its lead product LT-02 and is now in a position to proceed with a planned Phase III trial in the US in mild-moderate ulcerative colitis patients. The LT-02 IND was subject to the FDA's customary 30 day review period.
The 2010 report on universal access to HIV prevention, care and treatment released today by WHO, UNAIDS, and UNICEF shows continuing progress in scaling up global HIV/AIDS interventions.
› Verified 3 days ago
Thomas Nipper, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 60 Old New Milford Rd, Ste 3g, Brookfield, CT 06804 Phone: 203-775-6205 Fax: 203-775-2373 | |
Dr. Robert John Daher, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 60 Old New Milford Rd, Suite 3e, Brookfield, CT 06804 Phone: 203-775-6205 Fax: 203-775-2373 | |
Sanjay Kumar Gupta, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 60 Old New Milford Rd, Suite 3g, Brookfield, CT 06804 Phone: 203-775-6205 Fax: 203-775-2373 | |
Valdet Nikci, Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 60 Old New Milford Rd Ste 3e, Brookfield, CT 06804 Phone: 203-775-6205 Fax: 203-775-2373 | |
Daniel Nelson Fish, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 60 Old New Milford Rd, Ste 3e, Brookfield, CT 06804 Phone: 203-775-6205 Fax: 203-775-2373 |